Financial health
- Operating income covered interest expense -663.0× in the latest year.
- The company is unprofitable; at its current free-cash-flow burn it has roughly 2.4 years of cash runway.
IBIO Financials iBio, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2026 | $100000 | -$33M | 0.0% | -35141.0% | -38.6% | -33.3% | -$24M | — | $56M |
| 2025 | $400000 | -$18M | 0.0% | -4650.5% | -123.5% | -79.3% | -$15M | — | $9M |
| 2024 | $225000 | -$25M | 0.0% | -7392.9% | -116.8% | -86.7% | -$19M | — | $14M |
| 2023 | $0 | -$65M | — | — | -422.7% | -157.8% | -$36M | — | $4M |
| 2022 | — | -$50M | — | — | -79.2% | -50.6% | -$45M | — | $23M |
| 2021 | — | -$23M | — | — | -21.4% | -15.8% | -$35M | — | $77M |
| 2020 | — | -$16M | — | — | -29.0% | -17.5% | -$14M | — | $55M |
| 2019 | — | -$18M | — | — | -714.3% | -57.5% | -$15M | — | $4M |
| 2018 | — | -$16M | — | — | -99.6% | -37.4% | -$14M | — | $4M |
| 2017 | — | -$15M | — | — | -163.0% | -40.4% | -$14M | — | $16M |
| 2016 | — | -$10M | — | — | -98.3% | -18.9% | — | — | $16M |
| 2015 | — | -$7M | — | — | -59.0% | -53.0% | — | — | $9M |
| 2014 | — | -$4M | — | — | -60.1% | -56.5% | — | — | $4M |
| 2013 | — | -$6M | — | — | -122.3% | -66.3% | -$5M | — | $4M |
| 2012 | — | -$6M | — | — | -92.0% | -58.1% | -$6M | — | $6M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $0 | -$10M | — | — | -12.1% | -10.5% | -$6M | — | $56M |
| Mar '26 | $0 | -$8M | — | — | -10.0% | -9.0% | -$6M | — | $48M |
| Dec '25 | $0 | -$9M | — | — | -15.9% | -14.0% | -$6M | — | $29M |
| Sep '25 | $100000 | -$6M | 0.0% | -5951.0% | -10.2% | -8.9% | -$6M | — | $28M |
| Jun '25 | $200000 | -$5M | 0.0% | -2599.0% | -34.7% | -22.3% | -$5M | — | $9M |
| Mar '25 | $0 | -$5M | — | — | -42.7% | -25.4% | -$3M | — | $5M |
| Dec '24 | $200000 | -$4M | 0.0% | -2209.5% | -31.4% | -20.1% | -$4M | — | $7M |
| Sep '24 | $0 | -$4M | — | — | -22.5% | -16.3% | -$4M | — | $11M |
| Jun '24 | $175000 | -$8M | 0.0% | -1948.0% | -36.5% | -27.1% | -$5M | — | $14M |
| Mar '24 | $0 | -$3M | — | — | -12.8% | -6.3% | -$4M | — | $5M |
| Dec '23 | $0 | -$8M | — | — | -89.3% | -24.1% | — | — | $3M |
| Sep '23 | $50000 | -$6M | 0.0% | -10206.0% | -43.5% | -15.3% | — | — | $1M |
| Mar '23 | — | -$7M | — | — | -41.9% | -16.4% | -$4M | — | $7M |
| Dec '22 | — | -$34M | — | — | -178.3% | -64.8% | -$11M | — | $4M |
| Sep '22 | $0 | -$18M | — | — | -37.5% | -21.4% | -$16M | — | $10M |
| Jun '22 | — | -$17M | — | — | -26.9% | -17.2% | -$15M | — | $23M |
| Mar '22 | — | -$12M | — | — | -15.6% | -10.7% | -$7M | — | $34M |
| Dec '21 | — | -$12M | — | — | -13.2% | -9.4% | -$13M | — | $39M |
| Sep '21 | — | -$9M | — | — | -8.9% | -6.2% | -$10M | — | $63M |
| Jun '21 | — | $116000 | — | — | 0.1% | 0.1% | -$10M | — | $77M |
Valuation over time
How the market has priced IBIO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 585.9× (Jul '24) to 513.0× (Nov '26).
P/S
Frequently asked questions
Is IBIO growing its revenue and profit?
See the revenue and net-income charts above for iBio, Inc.'s multi-year trend.
How much debt does IBIO have?
As of FY2026, iBio, Inc. reported — of total debt against $56M of cash; operating income covered interest expense -663.0×.
What is IBIO's profit margin?
In FY2026, gross margin was —, operating margin -35141.0%, and net margin -33044.0%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.